united therapeutics glp-1 receptor agonist products How Agonists Evolved from Diabetes to Weight Loss Treatments GLP-1 Receptor Agonist Market Size

With the increasing use of Glucagon-Like Peptide-1 Receptor (GLP-1R) agonists for diabetes management and weight loss, their implications in perioperative care have gained attention

These medications also delay gastric emptying through neural mechanisms, increasing the risk for perioperative aspiration during anaesthesia and sedation

Since type 2 diabetes mellitus (T2DM) is a risk factor for Alzheimers disease (AD) and both have the same pathogenesis (e.g., insulin resistance), drugs used to treat T2DM have been gradually found to reduce the progression of AD in AD models

Originally developed and positioned as treatments for type 2 diabetes, these agents are now equally associated with weight management, reshaping how clinicians, patients, and pharmacies understand metabolic disease

Among the marketed large molecule injectable GLP-1 agonists, semaglutide, apart from weight-loss, is being studied for kidney disease and tirzepatide (a dual GLP-1 and GIP receptor agonist) is being evaluated for sleep apnea in Ph 3 clinical trials